Other analyses, such as the World Health Organization’s (WHO) Global Individual-Case-Safety-Report database [25] and a prospective observational surveillance study, reported a rate of 1.4% of myocarditis for single-agent treatment [46] and 1.7% to 2.4% for a combination ICI treatment, such as relatlimab (anti-LAG-3) plus nivolumab (anti-PD1) and ipilimumab (anti-CTLA4) plus nivolumab [28,39]. This evidence concerns the gene CTLA4 and myocarditis.